Component

Metabolic outcomes in nonobese postmenopausal women

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In nonobese postmenopausal women with normal glucose tolerance, 75 mg/day resveratrol for 12 weeks did not improve liver, muscle or adipose insulin sensitivity or measured AMPK/SIRT1/NAMPT/PPARGC1A targets.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Randomized double-blind placebo-controlled trial.
    limitations
    Null result is population- and regimen-specific.
    nutrient_topic
    Resveratrol collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Resveratrol
    plain_language
    Effects in metabolically abnormal models do not automatically transfer to healthy people.
    primary_references
    Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23102619/ · DOI 10.1016/j.cmet.2012.09.015

    Resveratrol: metabolites, target selectivity and cross-nutrient mechanisms (2026-09-19) · lines 470–476

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Randomized double-blind placebo-controlled trial. · source_derived_draft · unverified_draft

    ## resveratrol-human-women-null Effects in metabolically abnormal models do not automatically transfer to healthy people. In nonobese postmenopausal women with normal glucose tolerance, 75 mg/day resveratrol for 12 weeks did not improve liver, muscle or adipose insulin sensitivity or measured AMPK/SIRT1/NAMPT/PPARGC1A targets. Model: Randomized double-blind placebo-controlled trial. Limitations: Null result is population- and regimen-specific. Evidence access: Primary abstract Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23102619/ · DOI 10.1016/j.cmet.2012.09.015
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards